
Semaglutide Becomes the First ORAL GLP-1 Approved for Weight Loss
Episode 7
A new oral option is changing the GLP-1 landscape for weight loss, along with raising questions about efficacy, dosing, and when switching products makes sense. In this episode, TRC Healthcare Associate Editor and Clinical Pharmacist Vickie Danaher, PharmD discusses how semaglutide became the first FDA-approved oral GLP-1 agonist for obesity. She breaks down how it works, how it compares to injectable options, and dosing considerations for patients. Vickie also walks through key counseling points around administration, side effects, cost, and product mix-ups, and offers practical guidance on when switching between injectable and oral semaglutide may or may not be the right choice. This is an excerpt from our February 2026 Pharmacy Essential Updates continuing education webinar series. 🏷️ Use code cc1026 at checkout for 10% off a new or upgraded subscription. ****** CE Information: TRC Healthcare offers CE credit for this podcast for pharmacist subscribers at our platinum level or higher and pharmacy technician subscribers. Log in to your Pharmacist’s Letter or Pharmacy Technician’s Letter account and look for the title of this podcast in the list of available CE courses. None of the speakers have anything to disclose.
Publisher
Clinical Capsules - Actionable Medication Pearls in Minutes
Published
April 14, 2026
Duration
15 min
Format
Podcast
Category
Lifestyle · Courses
Source
RSS feed
Host
TRC Healthcare | Pharmacist's Letter | Prescriber Insights | Pharmacy Technician's Letter
Clinical Capsules - Actionable Medication Pearls in Minutes
@clinicalcapsulesactionableme
#semaglutidebecomes #oralglp #weightloss #medicine #courses
